These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24429011)

  • 1. Perampanel: a new agent for adjunctive treatment of partial seizures.
    Faulkner MA
    Am J Health Syst Pharm; 2014 Feb; 71(3):191-8. PubMed ID: 24429011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy.
    Faulkner MA
    Drug Des Devel Ther; 2017; 11():2921-2930. PubMed ID: 29042752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures.
    Owen RT
    Drugs Today (Barc); 2013 Jan; 49(1):23-31. PubMed ID: 23362493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
    Rektor I
    Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
    Faulkner MA; Burke RA
    Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.
    Ettinger AB; LoPresti A; Yang H; Williams B; Zhou S; Fain R; Laurenza A
    Epilepsia; 2015 Aug; 56(8):1252-63. PubMed ID: 26140524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.
    Schulze-Bonhage A
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
    Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S
    Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.
    Patsalos PN
    Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and development of perampanel for the treatment of epilepsy.
    Hanada T
    Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
    El Desoky ES
    Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
    Plosker GL
    CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
    Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
    Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
    Gidal BE; Majid O; Ferry J; Hussein Z; Yang H; Zhu J; Fain R; Laurenza A
    Epilepsy Behav; 2014 Jun; 35():6-12. PubMed ID: 24785428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatment options for epilepsy: focus on perampanel.
    Franco V; Crema F; Iudice A; Zaccara G; Grillo E
    Pharmacol Res; 2013 Apr; 70(1):35-40. PubMed ID: 23287426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.